Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomas

Neurooncol Adv. 2023 May 11;5(1):vdad061. doi: 10.1093/noajnl/vdad061. eCollection 2023 Jan-Dec.

Authors

Cecile Riviere-Cazaux¹, Jean M Lacey¹, Lucas P Carlstrom¹, William J Laxen¹, Amanda Munoz-Casabella¹, Matthew D Hoplin¹, Samar Ikram¹, Abdullah Bin Zubair¹, Katherine M Andersen¹, Arthur E Warrington¹, Paul A Decker¹, Timothy J Kaufmann¹, Jian L Campian¹, Jeanette E Eckel-Passow¹, Sani H Kizilbash¹, Silvia Tortorelli¹, Terry C Burns¹

Affiliation

¹ Departments of Neurological Surgery, Laboratory Medicine and Pathology, Neurology, Quantiative Health Sciences, Radiology, and Oncology, Mayo Clinic, Rochester, Minnesota, USA.

No abstract available

Keywords: 2-hydroxyglutarate; IDH; biomarker; glioma; monitoring.

Grants and funding